Back to Market返回行情

KALA KALA BIO, Inc.

USHealthcare
$1.18-12.96%ClosedMarket Cap: $25.8M

As of 2026-07-10 16:00

Why KALA matters now

KALA BIO, Inc. (KALA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.18 with -12.96% on the session and $25.8M in market capitalization; recent performance reads 1-month +42.69% and YTD -87.01%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.6M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -32.9%.

The latest indexable market news headline is "KALA BIO Announces Reverse Stock Split" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $18.25; recent insider activity includes Berger Chaim D. filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

2.73

P/S

0.00

EV/EBITDA

-4.50

DCF Value

$0.81

FCF Yield

-32.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-1335.6%

ROA

-159.6%

ROIC

-281.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-1.6M$-0.20
Q4 2025$0.00$686.0K$0.08
FY 2025$0.00$-27.0M$-3.31
Q3 2025$0.00$-7.6M$-1.07

Analyst Ratings

Consensus

Hold

Target (Consensus)

$18.25

Target (Median)

$18.25

Target Range

$1.50 - $35.00

Strong Buy: 0Buy: 0Hold: 1Sell: 0Strong Sell: 0
HC Wainwright & Co.Neutral
2025-09-29
HC Wainwright & Co.Buy
2025-09-17
OppenheimerOutperform
2025-09-11

Trading Activity

Insider Trades

Berger Chaim D.director:
Sell2026-02-09
Colman Yonatan C.director:
Sell2026-02-09
Minkowitz Avrahamdirector, officer: Chief Executive Officer
Sell2026-02-09
Posen Hillel D.director:
Sell2026-02-09
Purdy Brendan P.director:
Sell2026-02-09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

-2.41

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.